SCHEMBL4183371

SCHEMBL4183371

CC(=O)N(C)c1ccnc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
FSCN1 Q16658 1/20 0.42
SMARCA2 P51531 2/20 0.41
SMARCA4 P51532 2/20 0.41
RECQL P46063 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
POLB P06746 2/20 0.38
GRM5 P41594 1/20 0.37
RAB9A P51151 1/20 0.36
CCNC P24863 1/20 0.36
CDK8 P49336 1/20 0.36
PDK2 Q15119 1/20 0.35
ACLY P53396 1/20 0.35
NPC1 O15118 1/20 0.35
AHR P35869 1/20 0.35
BRD4 O60885 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
LOX P28300 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1400929 0.86 ALDH1A1 (0.46) ALDH1A1KDM4ESMARCA2SMARCA4RECQL
SCHEMBL1671876 0.77 ALDH1A1 (0.50) ALDH1A1KDM4ESMARCA2SMARCA4RECQL
SCHEMBL16992917 0.75 CCNC (0.35) ALDH1A1KDM4ESMARCA2SMARCA4RECQL
SCHEMBL22125208 0.73 CCNC (0.43) ALDH1A1KDM4ESMARCA2SMARCA4RECQL
SCHEMBL9414666 0.73 NAPRT (0.44) ALDH1A1FSCN1SMN1; SMN2POLBRAB9A
SCHEMBL4385687 0.72 KMT2A (0.53) ALDH1A1KDM4ESMN1; SMN2POLBRAB9A
SCHEMBL10865877 0.72 FSCN1 (0.50) ALDH1A1FSCN1SMN1; SMN2POLBRAB9A
SCHEMBL10277521 0.71 SMN1; SMN2 (0.45) ALDH1A1KDM4ESMN1; SMN2POLBRAB9A
SCHEMBL71090 0.71 SMARCA2 (0.41) ALDH1A1KDM4ESMARCA2SMARCA4RECQL
SCHEMBL17804146 0.71 RECQL (0.51) ALDH1A1SMARCA2SMARCA4RECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101080392-B Piperazinyl pyridine derivatives as anti-obesity agents HOFFMANN LA ROCHE 2010-05-05 CN disclosed
US-7612076-B2 Piperazinyl-pyridine derivatives HOFFMAN-LA ROCHE INC. (US) 2009-11-03 US disclosed
US-20090042903-A1 PIPERAZINYL-PYRIDINE DERIVATIVES NETTEKOVEN MATTHIAS HEINRICH 2009-02-12 US disclosed
US-7456175-B2 Piperazinyl-pyridine derivatives HOFFMAN-LA ROCHE INC. (US) 2008-11-25 US disclosed
EP-1828134-B1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS HOFFMANN LA ROCHE (CH) 2008-10-29 EP disclosed
CN-101080392-A Piperazinyl pyridine derivatives as anti-obesity agents HOFFMANN LA ROCHE (CH) 2007-11-28 CN disclosed
EP-1828134-A1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2007-09-05 EP disclosed
US-20060135528-A1 Piperazinyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2006-06-22 US disclosed
WO-2006063718-A1 PIPERAZINYL PYRIDINE DERIVATIVES AS ANTI-OBESITY AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135528-A1 Piperazinyl-pyridine derivatives HRH4, HRH3, H1-3 ALDH1A1 814/4885KDM4E 541/4885FSCN1 4858/4885
US-20090042903-A1 PIPERAZINYL-PYRIDINE DERIVATIVES HRH4, HRH3, H1-3 ALDH1A1 814/4885KDM4E 541/4885FSCN1 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.